OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD).ECCO'20 Vienna 2020
OP18: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's Disease: The SuPREMe-CD StudyECCO'20 Vienna 2020
OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017ECCO'20 Vienna 2020
OP23: Efficacy and safety of vedolizumab SC in patients with Moderately to Severely active Crohn’s Disease: Results of the VISIBLE 2 studyECCO'20 Vienna 2020
OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension studyECCO'20 Vienna 2020
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida RegistryECCO'20 Vienna 2020
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activityECCO'20 Vienna 2020
OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosaECCO'20 Vienna 2020
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trialECCO'20 Vienna 2020
OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epitheliumECCO'20 Vienna 2020
Pathogenesis, pathology and management of serrated lesions in IBD and non-IBD (Tandem talk)5th H-ECCO IBD Masterclass 2020